Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.72 EUR
Change Today -0.109 / -2.84%
Volume 847.6K
EVT On Other Exchanges
As of 3:35 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/25/14 - €4.33
52 Week Low
10/16/14 - €2.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG provides drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers a range of drug discovery services, such as anti-infectives, target identification and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism, and excretion) profiling, proteomics, cell and protein production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; Somatoprim that is in Phase II clinical trials for the treatment of Acromegaly; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, and EVT770 for diabetes type 2/1; and discovery stage products comprise various products for inflammation, diabetes type 2/1, kidney disease, oncology, Alzheimer’s disease, and CNS/MS. The company has alliances and partnerships with AstraZeneca AB, Bayer Pharma AG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., Jain Foundation Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Novartis AG, F. Hoffmann-La Roche AG, Shire plc, and UCB Pharma. It also has strategic collaboration with Fraunhofer Institute for Molecular Biology and Applied Ecology and Sanofi; and collaboration with Convergence Pharmaceuticals Holdings Ltd., Debiopharm Group, Eternygen GmbH, Medicines for Malaria Venture, and Second Genome, Inc. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

717 Employees
Last Reported Date: 03/6/15
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €459.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €323.0K
Chief Operating Officer and Member of Managem...
Total Annual Compensation: €361.0K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €361.0K
Compensation as of Fiscal Year 2014.

evotec ag (EVT) Key Developments

Asahi Kasei Pharma Selects Evotec as its Partner for Ion Channel Drug Discovery

Evotec AG announced that it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation. Under the terms of the agreement, Evotec will use its world-class ion channel platform to identify inhibitors of multiple ion channel targets.

Evotec AG Announces Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Evotec AG announced consolidated earnings results for the year ended December 31, 2014. For the year, the company's revenues were EUR 89.5 million compared with EUR 85.94 million a year ago. This increase is primarily due to continued growth in the EVT Execute base business. Operating loss was EUR 6.4 million compared with EUR 21.4 million a year ago. EBITDA adjusted was EUR 7.7 million compared with EUR 10.4 million a year ago. It was mainly impacted by the write-off of the Andromeda receivable. Net loss was EUR 6.98 million or EUR 0.05 per basic and diluted share compared with EUR 25.4 million or EUR 0.21 per basic and diluted share a year ago. For 2015, the group revenues excluding milestones, upfronts and licences expected to increase by more than 20% and adjusted EBITDA positive.

Evotec Seeks Acquisitions

In 2015, Evotec AG (XTRA:EVT) will continue to invest in its technology platforms and capacities in order to drive its long-term growth strategy. It is therefore planned that up to €10 million will be invested in further capacity increases and the upgrade of Evotec's technological capabilities. The company's mid-term financial plan does not envisage the need for any additional external financing for Evotec's operating business. However, all strategically desirable moves such as potential company or product acquisitions will need to be considered on a case by case basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €3.72 EUR -0.109

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.82 USD -0.09
Cytokinetics Inc $6.95 USD -0.18
Exelixis Inc $3.11 USD +0.01
GlaxoSmithKline SAE £11.12 EGP -0.16
Infinity Pharmaceuticals Inc $14.86 USD -0.28
View Industry Companies

Industry Analysis


Industry Average

Valuation EVT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at